.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

David S. Snyder, MD

Articles

Dr. Snyder on How Ruxolitinib and Fedratinib May Pave the Way to Transplant in Myelofibrosis

April 23rd 2020

David S. Snyder, MD, discusses how ruxolitinib and fedratinib may be used to pave the way toward transplant for patients with myelofibrosis.

Dr. Snyder on Tools to Improve Use of Allogeneic Stem Cell Transplant in Myelofibrosis

April 8th 2020

David S. Snyder, MD, discusses tools to improve the use of allogeneic stem cell transplant in myelofibrosis.

Dr. Snyder on Transplant Updates in Myelofibrosis

February 26th 2020

David S. Snyder, MD, discusses updates in treating patients with myelofibrosis who undergo transplant.

Dr. Snyder on the Utility of Transplant in MPNs

February 11th 2020

David S. Snyder, MD, discusses the utility of transplant in myeloproliferative neoplasms.

Dr. Snyder Discusses Ongoing Research in Myelofibrosis

September 6th 2019

David S. Snyder, MD, associate chair, Department of Hematology and Hematopoietic Cell Transplantation, professor, Hematology and Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope, discusses ongoing research in myelofibrosis.

Dr. Synder on the Quest to Revolutionize Management of Myelofibrosis

August 28th 2019

Dr. Snyder on Mainstays of Treatment in Polycythemia Vera

August 14th 2019

David S. Snyder, MD, associate chair and professor, Department of Hematology and Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope, discusses mainstays of treatment in polycythemia vera (PV).

Dr. Snyder Discusses Emerging Agents in Myelofibrosis

May 25th 2018

David S. Snyder, MD, associate chair and professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, discusses emerging agents in myelofibrosis.

Dr. Snyder on Ruxolitinib in Patients With Myelofibrosis

April 25th 2018

David S. Snyder, MD, associate chair and professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, discusses the use of ruxolitinib (Jakafi) in myelofibrosis.